Literature DB >> 28592156

Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.

Eli Muchtar1, Shaji K Kumar1, Hila Magen2, Morie A Gertz1.   

Abstract

Smoldering multiple myeloma (SMM) is a rare plasma cell disorder, and as the disease is asymptomatic, diagnosis is often incidental. SMM is characterized by increased marrow infiltration by clonal plasma cells and/or elevated serum M-protein in the absence of a myeloma-defining event (MDE). In recent years, SMM has gained increased attention owing to a broadening of the criteria for MDE, which include apart from the CRAB criteria, three additional parameters. Survival advantage may be offered by early treatment in the high-risk subset, based on a single trial. In this review, we assess the risk factors and models for progression to multiple myeloma. A review of our diagnostic and management approaches to SMM is presented.

Entities:  

Keywords:  Risk; early intervention; models; progression; survival

Mesh:

Substances:

Year:  2017        PMID: 28592156     DOI: 10.1080/10428194.2017.1334124

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

Review 1.  Nanotherapeutics for multiple myeloma.

Authors:  Alexander Zheleznyak; Monica Shokeen; Samuel Achilefu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

2.  Timing of treatment of smoldering myeloma: delay until progression.

Authors:  Shaji K Kumar
Journal:  Blood Adv       Date:  2018-11-13

3.  Early or deferred treatment of smoldering multiple myeloma: a meta-analysis on randomized controlled studies.

Authors:  Ai-Lin Zhao; Kai-Ni Shen; Ji-Nuo Wang; Lan-Qing Huo; Jian Li; Xin-Xin Cao
Journal:  Cancer Manag Res       Date:  2019-06-21       Impact factor: 3.989

Review 4.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

5.  Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathways.

Authors:  Alexander Zheleznyak; Matthew Mixdorf; Lynne Marsala; Julie Prior; Xiaoxia Yang; Grace Cui; Baogang Xu; Steven Fletcher; Francesca Fontana; Gregory Lanza; Samuel Achilefu
Journal:  Theranostics       Date:  2021-06-22       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.